<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>journal-jmsr</PublisherName>
      <JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Special Issue "Pathology"</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>March, 2023</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>JMSR Pathology</ArticleType>
      <ArticleTitle>Ret rearrangement in papillary thyroid carcinoma.</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1151</FirstPage>
      <LastPage>1151</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Fidélia Nihad</FirstName>
          <LastName>Da-Silva</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Sanaa</FirstName>
          <LastName>Hachimi</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Meriem</FirstName>
          <LastName>Regragui</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Asmae</FirstName>
          <LastName>Mazti</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Samira</FirstName>
          <LastName>Benayad</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Nisrine</FirstName>
          <LastName>Bennani-Guebessi</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Farida</FirstName>
          <LastName>Marnissi</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Mehdi</FirstName>
          <LastName>Karkouri</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Introduction: Papillary thyroid carcinoma accounts for 80% of all cases. The only documented risk factor for PTC is exposure to ionizing radiation. The prognosis is generally excellent. During the last 2 decades numerous studies on genetic alterations have demonstrated the pathogenic role of RET (rearranged during transfection) proto-oncogene rearrangements in PTC.&#13;
&#13;
Our work aims to investigate RET rearrangements in a series of papillary thyroid carcinoma.&#13;
&#13;
Materials and methods: This is a series of randomly selected cases of histological papillary thyroid carcinoma diagnosed at the laboratory of anatomy and cytological pathology of the CHU Ibn Rochd of Casablanca. To evaluate RET rearrangements, we performed FISH analysis on formalin-fixed and paraffin-embedded tissues using a RET gene break apart probe reagent.&#13;
&#13;
Results : A total of 12 cases of papillary carcinoma were collected. The average age of our patients was 48.8 years and all were female. The tumor size was variable with extremes between 15mm and 55mm long axis, and multifocal in 5 cases (41.7%).&#13;
&#13;
Among the histological subtypes, the vesicular and classical variants were the most frequent. Indeed, 4 cases (33.3%) of the vesicular variant and 4 cases (33.3%) of the classical variant were found, followed by the high cell variant in 2 cases (17%). Finally, the oncocytic variant was present in 1 case (8.7%) and the combination of vesicular and oncocytic variants also in 1 case (8.7%). Vascular emboli were present in 83.3% (10 cases) and extra-thyroidal extension in 5 cases. RET rearrangement was observed in 2 cases (16.7%) whose epidemiological and histological characteristics are described in the table.&#13;
&#13;
Conclusion: The search for molecular alterations in iodine-refractory thyroid carcinoma is desirable especially in view of the availability of systemic treatments and targeted therapies with promising results.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Papillary Thyroid Carcinoma, RET Rearrangement, Targeted Therapy</Keywords>
      <URLs>
        <Abstract>https://www.journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=14387&amp;title=Ret rearrangement in papillary thyroid carcinoma.</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. Int J Med Sci. 2019;16(3):450-460.&#13;
	Buffet C, Groussin L. Les grands acteurs de la tumorigenand;egrave;se thyroand;iuml;dienne et leurs consand;eacute;quences en pratique. MCED. 2015 ;14 : 36-38.&#13;
	Romei C, Elisei R. RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol. 2012; 3:54.&#13;
	Prescott JD, Zeiger MA. The RET oncogene in papillary thyroid carcinoma. Cancer. 2015; 121(13):2137-46.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>